Candidate vaccine [Refs.] | BGs production | Model/route/BGs dose | Assayed factor/results |
---|---|---|---|
EHEC O157H7 [26] | E-Lysis and SNUC | Mice/oral/4.8 × 109 BGs | IgG, IgA, IFNγ, cell proliferation/humoral and CMI response, protection against lethal heterologous challenge |
EHEC O157H7 [37] | E-Lysis and SNUC | Mice/rectal/4.8 × 109 BGs | IgG, IgA, IFNγ, cell proliferation/humoral and CMI response, protection against lethal heterologous challenge |
APEC O2 (DE17ΔluxSΔaroA) [36] | E-Lysis and SNUC | Chicken/S.C./109 CFU/0.3 mL | Histopathological analysis, IgG, IFNγ, TNF-α, IL-6/o pathological changes, IgG, IFNγ and TNF-α production |
APEC O2K1 [28] | E-Lysis | Chicken/Inha., Inj./1010 CFU/mL | IgY, IgA, IFNγ, lesion scores/IgY, IgA antibodies and IFNγ production, reduced lesions in internal organs |
APEC O78K80 [27] | E-Lysis | Chicken/Inha., Inj./1010 BGs/mL | IgY, IgA, IFNγ, lesion scores/IgY, IgA antibodies and IFNγ production, reduced lesions in internal organs |
APEC O78K80 (this study) | E-Lysis and SNUC | Chicken/Inha., Inj./1011 BGs/mL | IgY, IgA, IFNγ, cell proliferation, proinflammatory cytokines expression, lesion scores/humoral and CMI response, IL-6, IL-1β, and TNFα (TNFSF15) expression, reduced lesions in internal organs |